Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N07XX05

Amifampridine SERB(amifampridine phosphate)

Lambert-Eaton Myasthenic Syndrome;Paraneoplastic Syndromes, Nervous System;Nervous System Neoplasms;Paraneoplastic Syndromes;Nervous System Diseases;Autoimmune Diseases of the Nervous System;Neurodegenerative Diseases;Neuromuscular Diseases;Neuromuscular Junction Diseases;Immune System Diseases;Autoimmune Diseases;Autoimmune Diseases of the Nervous System;Cancer;Neoplasms

Marketing Authorisation Holder: SERB SA

EMA Authorisation: 19/05/2022

INN: amifampridine

Indication

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Amifampridine SERB — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Ask about Amifampridine SERBCreate Free Account

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.